To analyze the commercial dynamics of GLP-1 obesity drugs in comparison to Lipitor, highlighting potential risks from parallel imports and the implications for market structure.
Key Findings:
Lipitor's sales in Norway were significantly impacted by parallel imports during its patent period, with pharmacy chains favoring these imports for higher profit margins.
Pharmacy chains preferred parallel imports for higher profit margins, leading to a 90% market share in the atorvastatin segment.
Econometric modeling suggests Pfizer's sales could have been over 100% higher without parallel trade, highlighting the critical role of market structure.
Interpretation:
The findings indicate that GLP-1 drugmakers may face similar challenges as Lipitor due to structural market dynamics, the prevalence of parallel imports, and the influence of pharmacy chains.
Limitations:
The analysis is based on a specific case in Norway and may not fully represent other markets.
The focus on Lipitor may overlook other factors influencing GLP-1 drug adoption, and the variability of parallel import impacts across different countries.
Conclusion:
The Lipitor case serves as a cautionary tale for GLP-1 drugmakers regarding the risks of parallel imports and the importance of understanding market structure in Europe.
